NewTimeSpace News: August 19, 2026, SOFTCARE(02698.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 332.75 million, increased by 30.68% YoY.
NewTimeSpace News: August 20, 2026, AIA(01299.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 11.69 billion, increased by 11.69% YoY.
NewTimeSpace News: August 19, 2026, JIUYUAN GENE(02566.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 630.95 million, decreased by 1.23% YoY.
NewTimeSpace News: August 19, 2026, CMOC(03993.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 135.32 billion, increased by 42.78% YoY.
NewTimeSpace News: On 20 August 2026, LEADS BIOLABS-B (09887.HK) voluntarily announced that the Phase II study abstract of Vimx™ (a PD-L1/4-1BB bispecific antibody) in combination with chemotherapy as first-line NSCLC therapy has been published on the WCLC website, with an ORR of 65.0% and DCR of 95.0% in 60 evaluable patients and an ORR of 77.4% in the squamous subgroup; updated data from follow-up exceeding seven months will be presented orally at WCLC on 14 September.
NewTimeSpace News: On 20 August 2026, GENFLEET-B (02595.HK) voluntarily announced that a three-arm parallel-controlled Phase II study of oral KRAS G12D inhibitor GFH375 has been initiated for patients with previously treated KRAS G12D-mutated pancreatic cancer, including two first-in-class combination regimens (with cachexia bispecific GFS202A and pan-RAS inhibitor GFH276); GFH375 previously obtained breakthrough therapy designation in China and US FDA fast track designation.
NewTimeSpace News: On 19 August 2026, CHIHO ENV (00976.HK) voluntarily announced that, following the receivers' sale of the Scholz Group on 31 July 2026, the Company has filed a notice of discontinuance with the High Court of Hong Kong and served it on the defendants, terminating the relevant legal proceedings; the Company's shares remain suspended since 1 April 2025.
NewTimeSpace News: On 19 August 2026, GREENTECH INTL (00195.HK) announced that the Stock Exchange has notified that the last day of listing of its shares will be 21 August 2026, with the listing status cancelled from 9:00 a.m. on 24 August 2026; the Listing Review Committee has upheld the cancellation decision, and the shares will no longer be tradable on the Stock Exchange.
NewTimeSpace News: On 19 August 2026, CTR HOLDINGS (01416.HK) announced that its subsidiary Chian Teck has won the bid for land in Kaki Bukit, Singapore at SGD 52.788 million with a 33-year lease; as the applicable percentage ratios exceed 100%, the transaction constitutes a very substantial acquisition subject to EGM approval; the Company plans to build a multi-storey building with 407 dormitory beds and offices at a total cost of approximately SGD 102.79 million.
NewTimeSpace News: On 20 August 2026, SHOUCHENG (00697.HK) voluntarily announced that its fund has invested in Arctic Bear Chip Information Technology (Xi'an) Co., Ltd.; Arctic Bear Chip is an AI infrastructure service provider for large model applications with self-developed AI acceleration modules, chiplet and 3DDRAM technologies, and the investment will promote domestic substitution in full-scenario real-time inference.
NewTimeSpace News: On 19 August 2026, POLY XVERSE IT (00209.HK) announced that Kwok Kin Wai has resigned as Independent Non-Executive Director and committee member due to other business arrangements, with Ng Ka Yiu appointed in his place, both effective 19 August 2026; Mr. Ng has over 20 years of experience in capital market consulting, audit and tax advisory, with a monthly fee of HKD 10,000.
NewTimeSpace News: On 19 August 2026, LEADS BIOLABS-B (09887.HK) voluntarily announced that Oblenio Bio has exercised its option to retain the exclusive global license for LBL-051, with the Company to receive a one-time non-refundable fee of USD 10 million; LBL-051 is an immune reset candidate targeting BCMA, CD19 and CD3 for refractory autoimmune diseases.
NewTimeSpace News: On 19 August 2026, HENGRUI PHARMA (01276.HK) announced that its board proposed the adoption of the 2026 H-share scheme, granting awards in restricted share units with a mandate limit of not more than 1,000,000 H shares, representing approximately 0.4% of issued H shares, subject to Chapter 17 of the Listing Rules and effective upon a special resolution at an extraordinary shareholders' meeting.
NewTimeSpace News: On 19 August 2026, CONTINENTAL H (00513.HK) announced the disposal of the entire equity of a subsidiary holding a Boundary Street, Kowloon property for a total consideration of HKD 85 million, together with the transfer of approximately HKD 184.8 million of sale debts, constituting a very substantial disposal with an expected estimated loss of approximately HKD 135 million; trading was suspended on 19 August and is set to resume on 20 August.
NewTimeSpace News: On 19 August 2026, KEYMED BIO-B (02162.HK) announced that its board resolved to propose an issuance of ordinary shares to be listed on the STAR Market of the Shanghai Stock Exchange and traded in RMB, subject to market conditions, further board approval, shareholders' approval at a general meeting and necessary regulatory approvals; no application has been made to regulators as of the announcement date, and the issuance may not proceed.
NewTimeSpace News: On 19 August 2026, 5100 XIZANG (01115.HK) announced that its wholly-owned subsidiary entered into a distribution contract with Malaysia's Landmark Holding Sdn. Bhd., granting exclusive distribution rights in Malaysia and non-exclusive rights in Southeast Asian and Middle East export markets, with an initial three-year term renewable upon meeting performance targets, accelerating its overseas expansion.
